Product Spotlight - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Product Spotlight

Pharmaceutical Technology Europe


Probe enables monitoring of in-process vacuum



Hiden Analytical's in-process vacuum monitor, the HALO 201 MBE, was initially designed for application to the molecular beam epitaxy process and is suitable for use in difficult process conditions. Many vacuum-related processes operate at high- or ultra-high vacuum levels that represent a difficult environment for quadrupole mass spectrometers, but the sensitive ionisation region of the HALO 201 MBE probe is completely shrouded to inhibit random surface deposition. With a mass range of 1–200 amu, the probe can be used for measuring all common gasses and contaminants, and features operating modes for vacuum species identification, leak detection, and process trend analysis.

Hiden Analytical
http://www.hidenanalytical.com
Sensor is available worldwide

Pressure transmitter for efficient manufacturing processes



Honeywell's SmartLine industrial pressure transmitters are designed to enhance communication abilities, improve operational efficiency and reduce lifecycle costs for process manufacturers. The transmitters are intended to make it easier to support field devices and promote plant reliability with their efficiency-enhancing features, such as a graphic display capable of showing process data in graphical formats and communicating messages from the control room. SmartLine transmitters also feature modular components to simplify field repairs and reduce inventory required to make such repairs.

Honeywell Process Solutions
http://www.honeywellprocess.com/
Transmitters are available worldwide


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology Europe,
Click here